Stage III NSCLC RWE in Chinese Patients

CompletedOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

July 16, 2019

Primary Completion Date

February 29, 2024

Study Completion Date

February 29, 2024

Conditions
Carcinoma, Non-Small-Cell Lung
Trial Locations (25)

100020

Research Site, Beijing

100044

Research Site, Beijing

130021

Research Site, Changchun

200030

Research Site, Shanghai

200040

Research Site, Shanghai

330006

Research Site, Hefei

430079

Research Site, Shijiazhuang

530021

Research Site, Nanning

610041

Research Site, Chengdu

610042

Research Site, Chengdu

750004

Research Site, Yinchuan

2501117

Research Site, Jinan

Unknown

Research Site, Beijing

Research Site, Datong

Research Site, Fenyang

Research Site, Guangzhou

Research Site, Qingdao

Research Site, Shantou

Research Site, Taizhou

Research Site, Tianjin

Research Site, Hong Kong

Research Site, Shanghai

030000

Research Site, Datong

050011

Research Site, Shijiazhuang

063000

Research Site, Shijiazhuang

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY